Mumbai

Marksans Pharma, Headquartered in Mumbai (India) is vertically integrated global player with strong presence across the entire value chain from Active Pharmaceuticals Ingredient's (APIs) to formulations to biopharmaceuticals. We are also actively engaged in R&D and offers Contract Research and Manufacturing Services (CRAMS) to global pharmaceutical companies.

Medley was accredited as ISO - 9001 : 2000 company during the year 2003, by American Quality Assessors (AQA). Medley believes that quality is a continuous process and not an isolated stage in the process.
Medley's strength has also been it's product portfolio which has expanded in response to the market needs. As a strategic move towards success, the company has launched its cadiovascular, anti diabetic and neuropsychiatry products through its highly specialized VAZOKARE division.

P. D. Hinduja National Hospital & Medical Research Centre,  is an ultra modern tertiary care hospital, internationally acclaimed for it’s world class medical services with 381 inpatient beds including 57 critical care beds, covering all specialties and diagnostics. The inpatient services are complemented with a day centre, outpatient facilities and an exclusive centre for health check of executives.

USV is aleading healthcare company with the following areas of focus: Generics, Active Pharmaceutical Ingredients (APIs) and Biosimilars. 68% of our business is contributed by India Operations and the rest by export of APIs and Generics.
USV is a 48 year old healthcare company which began as a joint venture with USV&P Inc, a subsidiary of Revlon.

Flamingo Pharmaceuticals Ltd. is a quality driven pharmaceutical company with an experience of over two decades in global markets, exporting to 52 countries and having Rs.200 crores+ turnover. Flamingo has WHO-GMP/UK MHRA certified 100% EOU unit.

PreKlin Research Labs (Focus on US Biopharmas). Services through a joint US–India platform maximizing quality/FDA compliance and cost-efficiency. Focus on Exploratory and Pivotal Clinical Trials (NCEs and 505(b)2), Clinical End-Point Trials (Generics), BA/BE and Pre-clinical Studies
* Phase 1b and 2a Trials for NCEs
* Clinical Studies (PK/PD studies) for 505(b)2 filings (pilot and pivotal studies)
* Clinical End Point Trials for generic compounds (pilot and pivotal studies)